Lombardia: Gazzetta Medica Italiana
Tirzepatide activates both GLP-1 and GIP receptors, producing greater appetite suppression and metabolic effects than single-agent GLP-1 drugs
Wegovy is approved for weight loss, while Ozempic is for diabetes but may be prescribed for weight management
Often called the Triple G peptide, this investigational medication from Eli Lilly is showing results in clinical trials that we once thought were impossible without a scalpel
Over time, this impaired bile release can interfere with fat digestion and increase the likelihood of gallbladder dysfunction, particularly during rapid or prolonged medication-assisted weight loss
We offer cutting-edge GLP-1 therapies, including Semaglutide and Tirzepatide, to support weight management and metabolic health